Table 4.
Clinical and biological data of the “aging cohort”.
|
Normal eGFR (n = 48) |
Low eGFR (n = 48) |
P | |
|---|---|---|---|
| Age, years | 90 (85–92) | 90 (86–95) | 0.13 |
| Males, n (%) | 19 (40%) | 21 (44%) | 0.83 |
| BMI, kg/m2 | 22.4 (19.9–25.6) | 22.5 (20.2–24.0) | 0.25 |
| HBP, n (%) | 31 (65%) | 36 (75%) | 1.00 |
| Metabolic syndrome, n (%) | 6 (13%) | 7 (15%) | 0.27 |
| Anticoagulant therapy, n (%) | 13 (27%) | 17 (35%) | 0.63 |
| History of neoplasia, n (%) | 20 (42%) | 25 (52%) | 0.36 |
| RAS blockers, n (%) | 20 (42%) | 22 (46%) | 0.65 |
| Serum creatinine, μmol/l | 67 (58–77) | 117 (100–165) | < 0.001 |
| eGFR, ml/min/1.73 m2 | 76 (68–88) | 41 (34–50) | < 0.001 |
| Urinary Pu/Creat, mg/mmol | 24 (14–52) | 33 (15–122) | 0.30 |
| Urinary PAI‐1/Creat, pg/mmol | 10 (8–65) | 27 (10–196) | < 0.05 |
Data are expressed as median with interquartile (IQ25–IQ75) except if indicated. Fisher's exact test and Mann–Whitney U‐test were used for the comparison of qualitative and continuous variables, respectively.
BMI, body mass index; Creat, creatinine; eGFR, estimated glomerular filtration rate; HBP, high blood pressure; IQR, interquartile range; PAI‐1, plasminogen activator inhibitor 1; Pu, proteinuria; RAS, renin–angiotensin system.